(NBS:Consolidated Issue listed on NASDAQ Capital Market)
Alan G. Harris M.D., Ph.D., FACP FRCP
Vice President of Regenerative Medicine, Drug Development & Regulatory Affairs, Neostem, Inc.
|Age||Total Calculated Compensation||This person is connected to 5 board members in 1 different organizations across 4 different industries.|
See Board Relationships
Dr. Alan G. Harris, M.D. Ph.D. FACP FRCP has been Vice President of Regenerative Medicine Drug evelopment and Regulatory Affairs at Neostem Inc. since July 2009. Dr. Harris serves as an Officer of Ophthalmic Imaging Systems Inc. Dr. Harris served as Chief Medical Officer of Immune Pharmaceuticals Corp. since September 2011. Dr. Harris was responsible to develop Bertilimumab, company's phase II ready fully human monoclonal antibody for Crohn's Disease and lcerative Colitis ...
420 Lexington AvenuePhone: 212-584-4180
New York, New York 10170
Board Members Memberships*There is no Board Members Memberships data available.
Université de Strasbourg
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Dominick C. Colangelo Esq.||Chief Executive Officer, President, Treasurer and Director|
|Gil Van Bokkelen Ph.D.||Co-Founder, Chairman and Chief Executive Officer|
|Robin C. Stracey||Interim Chief Executive Officer, Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Governance & Nominating Committee|
Cesca Therapeutics Inc.
|Marc H. Hedrick M.D.||Chief Executive Officer, President, Director and Member of Executive Committee|
Cytori Therapeutics, Inc.
|Martin P. Rosendale||Chief Executive Officer and Director|
Nuo Therapeutics, Inc.
|$467.3K||Compensation as of Fiscal Year 2014.|